Healthcare has been slow to operationalize technological innovation. How we engage with providers today is not much different than decades ago. This has led to wasteful inefficiencies, persistent poor health outcomes, and out-of-control costs. AdviNow Medical is changing this paradigm. Using Artificial Intelligence and Augmented Reality to power a patient-friendly medical station, we have optimized the healthcare encounter—resulting in reduced overhead, greater patient through-put, billing timeliness and efficiency, and faster value-based, incentivized data collection.
Myriad RBM, Inc is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
PreAnalytiX, a joint venture between BD and QIAGEN, develops, manufactures and sells integrated and standardized systems for sample collection, stabilization and purification of high-quality RNA, microRNA and DNA from human blood, bone marrow, or tissue specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry with a broad array of manual and automated products.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenomic biomarkers for use within the pharmaceutical and biotechnology industries. The Company’s award-winning technology platform, EpiSwitch™, is designed to enable precision medicine programs by providing insights into disease mechanisms in early drug discovery, informing patient selection in clinical trials, and supporting product repositioning approaches. Oxford BioDynamics is headquartered in the UK and listed on the London Stock Exchange’s AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.?
For nearly 20 years, Ambry has been seeking to better understanding gene-disease relationships through collaboration, research, and innovation. We have identified novel genes, designed custom assays, and brought to market more than 500 unique diagnostic tests. We’ve been first-to-market with game-changing technologies, including clinical exome and hereditary cancer panels. With our committed team of experts, we are equipped with powerful technologies and stand by ready to develop custom assays to meet your specific criteria.
Invivoscribe® is a comprehensive CDx partner, providing ISO13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. We offer internationally standardized testing through our ISO15189 laboratory network (US, Europe, Asia). Our Streamlined CDx™ approach has proven successful in approval of the first-ever AML companion diagnostic – The LeukoStrat® CDx FLT3 Mutation Assay, helping pharmaceutical companies accelerate FDA and PMDA approvals of new targeted therapies for the most deadly form of leukemia.